Huntington’s disease, a fatal neurodegenerative condition that strikes in the prime of life, is caused by a single gene defect. The mutant gene was identified in 1993 but hope for a cure was far from assured as subsequent research revealed an amazingly complex role for this gene in brain function. Now, a positive phase I clinical trial and a $45 million bet from Roche suggests a reason for optimism. And if the therapy works for HD patients could a similar approach work for other neurodegenerative conditions?
Dr. George Rebec will talk about this work and the implications.
